Browse Articles

Discover research articles across all indexed journals

Unveiling ADAMTS12: A key driver of bladder cancer progression via COL3A1-Mediated activation of the FAK/PI3K/AKT signaling pathway

Journal of Biological Chemistry Jian-hua Xiao, Li-zhe Xu, Jin-zhuo Ning et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2025.108155

The effect of TU-100 on hepatocarcinogenesis and colorectal liver metastasis in MASH model.

Journal of Clinical Oncology Shinichiro Yamada, Yuji Morine, Tetsuya Ikemoto et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.577

577 Background: TU-100 is most commonly used herbal medicine in clinical setting. We have already reported that TU-100 suppressed dysbiosis (J Med Invest, 2013), bacterial translocation (Surg Today, 2017) and hepatic fibrosis (Surgery, 2016). This time we investigate the effect of TU-100 on hepatocellular carcinoma (HCC) and colorectal liver metastasis (CRLM) in MASH model. Methods: 1: Effect on HCC: Seven-week-old Tsumura Suzuki obese diabetes mice, a model that shows the spontaneous onset of MASH and HCC, were used. They were divided into a TU-100 treated group and a control group. Mice were sacrificed at 24 and 48 weeks to evaluate hepatic steatosis, fibrosis, carcinogenesis, cytokine expression, and microbiome abundance. 2: Effect on CRLM: Six-week-old male C57BL/6J mice were used. They were divided into the western diet (WD) group and the WD+TU-100 group. MC38 colon cancer cells were injected into the spleen at 16 weeks, and mice were killed at 2 weeks after injection to evaluate hepatic steatosis, fibrosis and mRNA expression in the liver. Results: 1: Effect on HCC: At 24 weeks, the TU-100 group showed significantly lower expression of IL6, IL1B, and ACTA2 mRNA in the liver (P<0.05). At 48 weeks, the TU-100 group showed a lower rate of MASH than the control group (28% vs 72%; P=0.1). Tumor diameter was significantly smaller in the TU-100 group compared with that in the control group (P<0.05). Regarding the intestinal microbiome, the genera Blautia and Ruminococcus were increased in the TU-100 group (P<0.05), whereas Dorea and Erysipelotrichaceae were decreased in the TU-100 group (P<0.05). 2: Effect on CRLM: Steatosis of the WD+TU-100 group was significantly suppressed compared with the WD group (p<0.05). The WD+TU-100 group showed significantly smaller tumor diameter than the WD group (p<0.05). In the WD+TU-100 group, expression of SAA1 and TIMP1 mRNA in the liver was significantly lower than in the WD group (p<0.05). Conclusions: TU-100 regulates the intestinal microbiome and may suppress hepatic steatosis and subsequent hepatocarcinogenesis in the MASH model. Furthermore, TU-100 may have effect on CRLM via suppression of SAA1/TIMP1.

A real-world study of treatment patterns among patients (pts) with metastatic colorectal cancer (mCRC) receiving third-line (3L) or fourth-line (4L) treatment in the US.

Journal of Clinical Oncology Huichu Li, Scott Kopetz, Yu Yin et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.64

64 Background: There are limited real-world data describing 3L and 4L treatments for pts with mCRC. However, the landscape is evolving with new options becoming available, including fruquintinib, a highly selective oral inhibitor of all 3 VEGF receptors, approved by the US FDA in November 2023. This study aimed to understand pt characteristics and real-world treatment patterns in 3L and 4L to characterize the standard of care, adherence to guidelines, and identify unmet needs among pts with mCRC in the US, prior to recent changes in the landscape. Methods: A retrospective study of adults with mCRC who had received ≥3L of therapy between 1/1/2018 and 3/31/2023 in the US-based Flatiron electronic health records database. In two cohorts, defined by initiating 3L and 4L systemic treatment, pt demographics, clinical characteristics, and treatment by line of therapy were summarized. Results: Overall, 5401 pts were included in the 3L cohort and 2868 pts in the 4L cohort: median age at baseline was 63 and 62 years (yrs), 56% and 56% were male, 43% and 43% had a KRAS variant, and 46% and 49% had liver metastasis, respectively. 96% of pts in the 3L cohort received standard chemotherapy (CT) +/- targeted therapy as 1L treatment (55% CT + anti-vascular endothelial growth factor [VEGF] therapy; 34% CT only; 7% CT + anti-epidermal growth factor receptor [EGFR] therapy). In 2L, 87% of pts had standard CT-containing regimens (53% CT + anti-VEGF therapy; 19% CT alone; 15% CT + anti-EGFR therapy). A similar treatment history was observed for the 4L cohort. Commonly used 3L regimens in the 3L cohort were trifluridine/tipiracil (TAS-102; 11%), regorafenib (rego; 10%), and standard CT-containing regimens (54%; including: 12% FOLFIRI + bevacizumab [bev], 7% FOLFOX + bev, 4% FOLFIRI, 3% FOLFOX, and 15% standard CT + anti-EGFR therapy). Approximately 47% (n=2513) of pts did not receive subsequent treatments after 3L. In the 4L cohort, use of TAS-102 (16%) and rego (15%) increased slightly in 4L, accompanied with a moderate decrease in CT-containing regimens (42%; including 6% FOLFOX + bev, 5% FOLFIRI + bev, 3% FOLFOX, 3% FOLFIRI, and 12% standard CT + anti-EGFR therapy). Approximately 4% of pts in the 3L and 4L cohorts received TAS-102 + bev in 3L and 4L, respectively. Pts receiving standard CT-containing regimens were slightly younger (<65 yrs: 3L 57%, 4L 58%) and had better Eastern Cooperative Oncology Group performance status (ECOG PS; 0-1: 3L 77%, 4L 77%) vs pts receiving TAS-102 (<65 yrs: 3L 54%, 4L 58%; ECOG PS 0-1: 3L 70%, 4L 68%) or rego (<65 yrs: 3L 50%, 4L 53%; ECOG PS 0-1: 3L 68%, 4L 70%). Conclusions: Characterization of treatment patterns in US pts from 1/2018 to 3/2023 showed that standard CT +/- targeted therapy was used frequently in 3L and 4L, demonstrating an unmet need for additional therapies. Approval of novel treatments, such as fruquintinib, may help to address this need.

Differential gut microbiota profiles among normal colorectal mucosa, adenomatous and hyperplastic polyps in healthy volunteers: ColoMAR-1 study.

Journal of Clinical Oncology Maria Dolores Martos-Morillo, Idoia Sanluis, Jose M Cardenas et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.271

271 Background: Increasing evidence indicates that the interaction between intestinal microbiota and host cells plays an important role in colorectal cancer oncogenesis through immune, inflammatory and/or metabolic alterations. However, there are no clear evidence in the very early adenoma-carcinoma sequence at which microbiota species influences future steps to colorectal carcinoma. This study aims do find a point in the adenoma-carcinoma sequence ad witch microbiota species suggest the risk of a future tumor to develop less invasive forms of early diagnosis. Methods: In this cross-sectional study, healthy volunteers above 45 years old were selected to participate. Exclusion criteria includes previous colonoscopy performed in the last 5 years. Stool sample were collected before a colonoscopy with biopsy. Samples of normal mucosa were systematically obtained, and all polyps found were removed. In fecal samples, microbiota species were identified using GoodGut test: Bacteroides fragilis, Subdoligranulm variabile, Ruminococcus, Roseburia, Coprococcus , eubacteria, Faecalibacterium prausnitzii and Gemella morbillorum . Number of genomic copies/μL were analyzed using the Wilcoxon test. Results: From February to June 2024, 29 healthy volunteers between 45 and 69 years were recruited. 62% were female. Adenomatous polyps or hyperplastic polyps were found in 9 volunteers. No case of colorectal cancer was found. For species S. variabile, Ruminococcus, Roseburia, Coprococcus and F. prausnitzii , higher counts were found in stool samples from volunteers with adenomatous or hyperplastic polyps than in those from volunteer with a normal colonoscopy, both in the total count and after correction for bacterial load (p<0.001). For B. fragilis , bacterial count was higher in samples from volunteers with adenomatous polyps, but not in the samples from people with hyperplastic polyps compared with those samples from volunteers with a normal colonoscopy. G. morbillorum counts were not related to any type of polyps. None of this counts met the laboratory-designated threshold related to colorectal cancer. Conclusions: The presence of B. fragilis could be related to the differential risk of malignancy of adenomatous compared to hyperplastic polyps. Bacterial count for each sample and specie. Bacteria specie* Normal mucosa Adenoma Hyperplastic B. fragilis 22.13 22.3 20.42 S.variable 6.06 7.29 7.53 Ruminococcus, Roseburia, Coprococcus 6.08 7.29 7.47 F. prausnitzii 4.7 6.28 7.09 G.morbillorum 20.91 20.54 20.84 *Number of genomic copies/μL.

Real-world use of supportive medications to prevent and manage key adverse events during first-line (1L) treatment of metastatic pancreatic adenocarcinoma (mPDAC) with FOLFIRINOX (FFX), FFX without 5FU bolus, and gemcitabine+nab-paclitaxel (GnP).

Journal of Clinical Oncology Syvart Dennen, Marty Masek, Paul Cockrum et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.695

695 Background: 1L treatment of mPDAC with FFX or GnP typically requires supportive care to alleviate toxic effects. Two of the most common adverse events are neutropenia, which may be treated with granulocyte colony-stimulating factor (G-CSF), and diarrhea, often treated with atropine and/or loperamide. Medications may be administered as prophylaxis (PPx) or to manage symptoms as they occur. Other methods to improve tolerability include modifying regimens with lower doses or omitted components, such as removing the 5FU bolus from FFX (FFXnb). This study examines PPx vs non-PPx G-CSF, atropine, and loperamide during 1L treatment with FFX, FFXnb, and GnP. Methods: This retrospective observational study utilized Optum Market Clarity claims + EHR linked data. Inclusion criteria were: adult patients (pts) diagnosed with mPDAC between January 1, 2015 and May 31, 2023; initiated treatment (index date) with 1L FFX, FFXnb, or GnP -14 to +90 days from diagnosis; no evidence of other cancers in 6 months pre-index continuous enrollment; at least one EHR record post-index. G-CSF PPx was defined as administration/fill within 7 days of the start of a treatment, inclusive. PPx with atropine or loperamide was defined as administration/fill the day before or day of a treatment; all other use was categorized “non-PPx”. Pts may appear in both PPx and non-PPx categories. Results: Rates of overall use, PPx, and non-PPx for each medication of interest are shown (Table). The overall G-CSF use rate was >3.5 times higher for FFX and FFXnb vs GnP. While ≥70% of FFX/FFXnb pts received PPx, non-PPx still occurred in more than 1 in 8 pts. One-fifth of FFX and FFXnb pts received atropine at any time, vs. just 6% of GnP pts. Atropine PPx was less common than non-PPx for FFX/FFXnb and was rare in GnP pts. Similar to the other medications, loperamide was observed more for FFX and FFXnb vs. GnP, but was the least common of the medications, used by <10% of pts in any regimen. PPx and non-PPx use were similar. Use of the three medications was similar between FFX and FFXnb. Conclusions: In a RW cohort of 1L mPDAC pts, G-CSF and antidiarrheal use was more common in FFX and FFXnb than GnP pts. Most FFX and FFXnb pts received PPx G-CSF, reflecting clinician efforts to manage the high risk of neutropenia with these regimens. Non-PPx G-CSF still occurred in 14–18% of pts. FFXnb had similar rates of concomitant medications as FFX, indicating that removing the 5FU bolus may have minor impact on the need for some supportive medications. Concomitant medication use. Medication 1L FFX(n=511) 1L FFXnb(n=583) 1L GnP(n=958) G-CSF % treated overall 77% 71% 20% % PPx 76% 70% 17% % non-PPx 18% 14% 9% Atropine % treated overall 20% 20% 6% % PPx 11% 9% 2% % non-PPx 15% 16% 5% Loperamide % treated overall 7% 9% 3% % PPx 4% 5% 1% % non-PPx 4% 6% 2%

The C-terminal α-helix is crucial for the activity of the bacterial ABC transporter BmrA

Journal of Biological Chemistry Veronika Osten, Kristin Oepen, Dirk Schneider Feb 01, 2025 DOI: 10.1016/j.jbc.2024.108098

The prognostic value of HER2 gene dosage and heterogeneity at a single-cell resolution in gastroesophageal adenocarcinoma.

Journal of Clinical Oncology Yashika Parashar, Leigh Culnane, Joshua Remland et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.473

473 Background: HER2 gene dosage (i.e. level of amplification) and heterogeneity are key prognostic variables for HER2+ gastroesophageal adenocarcinoma (GEA), yet no standardized approach to test these in routine clinical use exists. Here we modify the analytical pipeline for HER2 FISH to quantitatively estimate these prognostic variables and correlate them with clinical outcomes. Methods: Patients with metastatic HER2+ GEA who received trastuzumab-based therapy between 2011-2024 at Dana-Farber Cancer Institute and had available pre-treatment tissue for FISH analysis were included. HER2 FISH was conducted in a CLIA approved clinical pathology laboratory. Standard HER2/CEP17 ratio (an average of 50 cells) and individual cell HER2/CEP17 ratio were calculated. Kaplan-Meier method was used to estimate progression free (PFS) on trastuzumab-based therapy and overall survival (OS). Survival outcomes were adjusted for age, gender, tumor site, grade, prior resection, number of metastatic sites, and HER2 IHC using cox proportional hazard regression models. Results: A total of 77 patients were included. Median age was 60 years, 88% were male, and 92% had HER2 3+ tumors. Individual cells with HER2/CEP17 ratio ≥ 2.0 were defined as amplified (same cutoff as current bulk standard) and those with HER2/CEP17 ratio ≥ 4.95 (population median) were labeled highly HER2 amplified providing objective metrics to assess heterogeneity and gene dosage. Using these metrics we defined three subgroups: 1. Heterogenous (Het, n = 15): <75% cells HER2+; 2. Homogenous, low gene dosage (HL, n = 30): >75% cells HER2+, <50% cells with high HER2 amplification; 3. Homogenous, high gene dosage (HH, n = 32): >75% cells HER2+, >50% cells with high HER2 amplification. Cutoffs for both metrics were determined using data distribution patterns. The subgroups were prognostically relevant and PFS and OS were significantly lower for heterogenous tumors and numerically lower for homogenous tumors with low gene dosage after multivariable adjustment (Table). Conclusions: HER2 gene dosage and heterogeneity significantly impact outcomes in HER2+ GEA. More importantly by deconvoluting clinical HER2 FISH data at single cell level, we demonstrate an objective metric with prognostic value that could be adopted for routine clinical use and for patient stratification. Further insights into differing biology of these molecular subtypes are needed. Outcomes of patients by HER2 heterogeneity and gene dosage. Hazards ratio (HR) and p values are adjusted using multivariable cox proportional hazard regression model. PFS OS Patients, No. Median, mo HR (95%CI) P Value Median, mo HR (95%CI) P Value HH 32 16.2 1 16.4 1 HL 30 12.1 1.70 (0.79-3.66) 0.173 15.7 1.71 (0.93-3.14) 0.085 Het 15 6.7 3.12 (1.35-7.2) 0.008 12.4 2.72 (1.28-5.75) 0.009

First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors.

Journal of Clinical Oncology Jayesh Desai, Sophia Frentzas, Marwan Fakih et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.123

123 Background: BGB-B167 is potentially a first-in-class IgG-based bispecific antibody that targets CEA, a tumor-associated antigen overexpressed in many cancers, and 4-1BB, a key T-cell co-stimulatory receptor expressed on activated CD4+/CD8+ T lymphocytes. Preclinical data suggest BGB-B167 binds to these target proteins with high specificity/affinity, inducing T-cell activation and antitumor activity, with potential for mitigating strong AEs, eg CRS and hepatoxicity. We present results of a first-in-human, phase 1a, open-label, multicenter trial of BGB-B167 given as monotherapy (Part A [A]) or with tislelizumab (TIS) (Part B [B]) (NCT05494762). Methods: Eligibility: ≥18 y with unresectable/metastatic CRC, CEA+ GC or CEA+ NSCLC previously treated with standard systemic therapy or for whom treatment is unavailable; pts with CRC and known MSI-H/dMMR status must have received prior ICI, if available. Primary objectives: safety/tolerability; MTD and RP2D for BGB-B167 ± TIS; key secondary objective: antitumor activity (RECIST v1.1). Results: As of July 7, 2024, 54 pts were enrolled (31 in A, 23 in B) with BGB-B167 dose ranges of 5–1200 mg IV QW assessed in A and 50–600 mg IV QW in B. In A and B, respectively, 29/31 (93.5%) and 18/23 (78.3%) had CRC, 2/31 (6.5%) and 3/23 (13%) had GC, 0/31 (0%) and 2/23 (8.7%) had NSCLC; 19/31 (61.3%) and 18/23 (78.3%) had liver metastases; 20/31 (64.5%) and 14/23 (60.9%) received ≥3 lines of prior therapy. TEAEs occurred in all pts (Table). Most common treatment-related TEAEs were nausea (4/31; 12.9%) and fatigue (3/31; 9.7%) in A and pruritus (5/23; 21.7%) and diarrhea (4/23; 17.4%) in B; there were no treatment-related TEAEs indicative of hepatotoxicity or CRS. There was a single DLT (gr 3 SJS) in a pt who received 600 mg BGB-B167 + TIS (resolved after treatment discontinuation). MTD was not reached. 3 pts (1 with CRC [A]; 1 with CRC and 1 with GC [B]) had confirmed PRs. DoR was ≥5.6 mo for the pt in A and ≥5.6 mo and ≥6.9 mo for the pts in B; all remained on treatment with ongoing responses as of the data cutoff date. DCR (95% CI) was 33.3% (17.3–52.8) in A and 40.9% (20.7–63.6) in B. Serum exposure of BGB-B167 increased dose dependently from 150 to 1200 mg. Conclusions: Overall, BGB-B167 ± TIS was well tolerated and has demonstrated limited antitumor activity in pts with advanced/metastatic CEA+ solid tumors. Clinical trial information: NCT05494762 . Safety. Part ABGB-B167 monotherapy(N=31) Part BBGB-B167 + TIS(N=23) Any TEAE 31 (100.0) 23 (100.0) Any treatment-related TEAE 17 (54.8) 15 (65.2) Gr ≥3 4 (12.9) 1 (4.3) Serious 0 (0) 2 (8.7) Leading to death 0 (0) 0 (0) Leading to treatment discontinuation 0 (0) 1 (4.3) Any imAE 2 (6.5) 5 (21.7) IRRs 4 (12.9) 6 (26.1) Patients with multiple adverse events (AEs) are counted once. All AEs are listed as n (%). imAE, immune-mediated AE; IRR, infusion-related reaction; TEAE, treatment-emergent AE.

Molecular characteristics and prognostic impact of <i>GNAS</i> mutations in colorectal cancer: An international collaborative study between United States and Japan.

Journal of Clinical Oncology Elisabeth Arrondo, Naoko Iida, Tadayoshi Hashimoto et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.48

48 Background: GNAS (Guanine nucleotide-binding protein, alpha stimulating) encodes the alpha subunit of the stimulatory G protein, and gain of function mutations in this gene have been previously identified, especially those located at the R201 codon. Although GNAS R201C/H has been associated with mucinous histology and poor response to chemotherapy in appendiceal cancer, the impact of GNAS mutations in colorectal cancer (CRC) remains unclear. Methods: We conducted a comparative, integrative analysis of GNAS mutations in CRC using two cohorts: MD Anderson Cancer Center (MDA) across all stages (N=5,249) and the GALAXY study involving only resectable disease (UMIN000039205, N=2,599). We assessed the correlation between GNAS pathogenic mutations and microsatellite stability, CRC sidedness, co-mutations, and survival outcomes. The Chi-squared test was used for categorical variables, and the log-rank test for overall survival (OS) and disease-free survival (DFS). Results: In the MDA and GALAXY cohorts, GNAS mutations were identified in 107 (2.0%) and 61 (2.4%) patients, respectively. Prevalence of GNAS mutations was higher in right sided tumors (MDA: 3.8% vs. 1.3%, GALAXY: 6.2% vs 2.8%, p&lt;0.01 for both cohorts) and microsatellite instability-high (MSI-H) tumors (MDA: 6.5% vs. 1.8%, GALAXY: 16.5% vs. 1.4%, p&lt;0.01 for both cohorts). There was not an association of GNAS mutations with stage in either cohort. GNAS was significantly enriched for co-mutation with KRAS in the MDA cohort (OR=3.26, P&lt;0.01), similar to prior observations in appendix cancer, but was not significantly associated with KRAS mutations in the GALAXY cohort (OR=1.35, P=0.3). GNAS mutations were mutually exclusive with TP53 in both cohorts (MDA: OR=0.58, P=0.026; GALAXY: OR=0.21, P&lt;0.01). With regards to survival, in the MDA cohort, GNAS mutant tumors had a trend towards worse OS in the overall population (20 mo vs. 33 mo, HR=1.27, 95% CI=0.61-1, P=0.085). The survival impact of GNAS mutations was greatest in metastatic patients (Stage IV: 19 mo vs. 38 mo, HR=1.49, 95% CI=0.47-0.94, P=0.021 vs. Stage I-III: HR=1.35, 95% CI=0.46-1.2, P=0.22). The GALAXY cohort showed no significant association between GNAS mutations and DFS (HR=1.05, 95% CI=0.6-1.8, P=0.9). In both cohorts, GNAS mutations had a worse prognosis in left-sided CRC (MDA: HR for OS = 1.45, P = 0.091; GALAXY: HR for DFS=2.15, P=0.09) with no significant effect observed in right-sided CRC (MDA: HR for OS=0.91, P=0.68; GALAXY: HR for DFS=0.65, P=0.3). Conclusions: Our findings highlighted the intricate role of GNAS mutations in CRC, demonstrating its higher prevalence in MSI-H and right-sided colon, significant association with KRAS mutations, and divergent prognostic impacts based on tumor sidedness. Further research is needed to elucidate the mechanisms behind the worsened survival in left-sided GNAS- mutated CRC.

Management of patients with locally advanced rectal cancer in the total neoadjuvant therapy (TNT) era: Experience from Argentina.

Journal of Clinical Oncology Maria Victoria Faura, Maria del Rosario Sifon, Mercedes Tamburelli et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.85

85 Background: In the last years a paradigm shift has changed the way we manage non metastatic rectal cancer. The varied options within TNT have gradually been adapted in our country. This study aims to depict the strategies implemented. Methods: A prospective and retrospective observational study was performed from 2020 to 2024 including stage II-III rectal cancer patients treated at three centers in Buenos Aires, Argentina. Data was extracted from medical records. Results: 68 patients were included in the analysis. Median age was 59 years (IQR 48–71). 72% were male. 88% (60) had stage III disease, and 12% (8) stage II. Geriatric assessment was performed in 7 of 19 patients aged over 70 (5 frail). All patients were staged with high resolution MRI and discussed in multidisciplinary tumor board. Mismatch repair was assessed in 72%(49) of patients, only one had MLH1 deficiency. 79%(54) patients received TNT: 22%(12) short course vs 78%(42) long course radiotherapy; 24%(13) induction vs 76%(41) consolidation chemotherapy. Preferred chemotherapy regimen was CAPOX both in induction and consolidation chemotherapy (69.7% and 63.4%, respectively) Despite small numbers non significant differences in risk factors were found between TNT vs non TNT groups (Table). We registered 13 Grade 3-4 toxicity events: 3 in induction chemotherapy, 7 in consolidation and 3 in radiotherapy. Clinical complete response was achieved in 25.9% of TNT (11 consolidation, 3 induction) and 7.1%(1) of non-TNT (p=0.25). Watch and Wait was employed in 9 patients in TNT and 1 in non TNT group. 40 patients underwent surgery in the TNT and 11 in the non-TNT group; complete pathological response was reached in 17.5% (7) and 9% (1), respectively. Overall relapse rate was 19.14% (13): 2.94% (2) local and 16.2% (11) systemic. (TNT: 1.85%(1) local vs 18.5%(10) metastatic; nonTNT: 7.14%(1) both local and metastatic) p=0.4. At a median follow-up of 20 months (IQR 15–32 months), 2-year progression-free survival (PFS) rate was 87% (95% CI: 38–98%) in the non-TNT group and 78% (95% CI: 61–88%) in the TNT group. Conclusions: This study highlights the feasibility of worldwide adoption of TNT. We describe the preferred regimens and results of TNT in three high volume centers in Argentina. Long course radiotherapy and consolidation treatment with CAPOX are the predominant strategies. Non operative management is routinely offered to complete responders. Our efficacy results are comparable with published literature. Comprehensive geriatric assessment is recommended but still partially applied. In line with recent findings MMR testing has been widely adopted as an initial workup parameter. TNT %(n=54) non-TNT %(n=14) p T4 disease 26 (14) 21 (3) 0.99 N2 37 (20) 29 (4) 0.75 EMVI positivity 49 (26) 18 (3) 0.16 Circumferential resection margin &lt;1 mm 29.6 (16) 28.57 (4) 0.23 Low-lying tumors 33 (18) 43 (6) 0.54

New insights in uranium bioremediation by cytochromes of the bacterium Geotalea uraniireducens

Journal of Biological Chemistry Alexandre Almeida, David L. Turner, Marta A. Silva et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2024.108090

Relationship between PD-L1 expression and the number of biopsy specimens in advanced gastric cancer.

Journal of Clinical Oncology Taro Mizuno, Yukiya Narita, Yasunobu Ishizuka et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.481

481 Background: Programmed cell death ligand 1 (PD-L1) expression shows spatial heterogeneity in gastric cancer. Compared with single biopsies, multiple biopsies may provide reliable PD-L1 expression results. However, the optimal number of biopsy specimens remains unclear. This study aimed to assess the relationship between PD-L1 expression and the number of biopsy specimens in advanced gastric cancer. Methods: We retrospectively analyzed patients with advanced gastric cancer who received first-line chemotherapy at a single institution between December 2021 and June 2024. Those in whom PD-L1 expression was evaluated using tumor-containing biopsy specimens were included. PD-L1 expression was measured using the Dako PD-L1 IHC 28-8 pharmDx assay. PD-L1 positivity was defined as a combined positive score of ≥5. The association between PD-L1 positivity and the number of biopsy specimens was tested using the chi-square or Fisher’s exact test. Results: Of the 183 patients screened, 110 were included. The patient characteristics were as follows: median age, 71 (range: 34–87) years; sex (male/female), 75/35; primary site (gastric/gastroesophageal junction), 102/8; and histological type (diffuse/intestinal/other), 59/34/17. The PD-L1 positivity prevalence was 71.8%. In 97 patients, human epidermal growth factor receptor 2 (HER2) expression was detected in the same specimens as PD-L1, with a HER2-positive rate of 14.4%. The mean numbers of biopsy and tumor-containing biopsy specimens were 5.14 (range: 2–10) and 4.25 (range: 1–10), respectively. The PD-L1 positivity prevalence was significantly higher when the number of biopsy specimens was ≥5 compared with ≤4 (77.5% vs 56.7%, P =0.03; Table). The same trend was observed according to the histological type (diffuse type, 75.0% vs. 46.7%, P =0.04; intestinal type, 79.2% vs. 60.0%, P =0.39). In HER2-negative cases, PD-L1 positivity was significantly more prevalent when the number of biopsy specimens was ≥5 compared with ≤4 (83.6% vs 54.5%, P =0.006; Table). However, there was no such difference in HER2-positive cases (54.4% vs 66.7%, P =1). Conclusions: The data suggest that collecting at least five biopsy specimens increases the likelihood of identifying PD-L1 positivity in advanced gastric cancer, particularly in HER2-negative cases. This approach may improve PD-L1 evaluation accuracy and lead to better treatment decisions. Relationship between the number of biopsy specimens and PD-L1 positivity. Number of biopsy specimens PD-L1 positivity (%) PD-L1 negativity (%) P value Overall 0.03 ≥5 77.5 22.5 ≤4 56.7 43.3 HER2-negative 0.006 ≥5 83.6 16.4 ≤4 54.5 45.5

Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors.

Journal of Clinical Oncology Kyriakos P. Papadopoulos, Michael Cecchini, Moh'd M. Khushman et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.tps322

TPS322 Background: Wnt/B-catenin pathway activation, which is frequently present in most colorectal cancers and a variety of other solid tumors, is associated with poor prognosis and resistance to immunotherapy. FOG-001 is a Helicon peptide that competitively inhibits the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors. Experiments in patient-derived-xenograft (PDX) models of colorectal cancer (CRC) and hepatocellular carcinoma (HCC) have demonstrated that FOG-001 can inhibit tumor growth and promote tumor regression when administered as monotherapy or in combination with immune checkpoint inhibitors or standard of care therapies, including bevacizumab and 5-FU. Methods: This first-in-human, Phase 1/2, multicenter, open-label, dose escalation (Part 1) and dose-expansion (Part 2) study evaluates the safety/tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor effects of FOG-001 as monotherapy and in combination with other anti-cancer therapies. Eligible patients must have received at least one prior systemic anti-cancer therapy and either progressed on, not responded to, or be unfit for available therapies. In Part 1, FOG-001 is administered intravenously, either weekly or every other week, at escalating dose levels evaluated sequentially in a standard 3+3 design as monotherapy in patients with: (1a) microsatellite stable (MSS) CRC or any solid tumor with a documented Wnt/b-catenin pathway activating mutation (WPAM) and (1c) HCC with WPAM. Part 1b will evaluate PD effects in cohorts of approximately six patients with MSS CRC. Upon selection of the preliminary recommended Phase 2 dose from Part 1a for weekly dosing, combination dose escalation (1d) evaluates the safety/tolerability, PK and anti-tumor effects of FOG-001 in CRC patients combined with FOLFOX+bevacizumab, anti-PD-1/PD-L1 (also includes other solid tumors with known WPAM), or trifluridine/tipiracil+bevacizumab. Part 2 dose expansion evaluates FOG-001 monotherapy in MSS CRC, HCC, and other solid tumors with documented WPAM. Combination dose expansion evaluates the combinations initially evaluated in Part 1d. Primary endpoints are safety/tolerability and preliminary anti-tumor effects (objective response rate). Secondary endpoints are PK, PD, and other anti-tumor responses (e.g., best objective response, duration of response, and progression free survival). Enrollment in Parts 1 and 2 is ongoing in the USA. Clinical trial information: NCT05919264 .

Tumor lysis syndrome in colorectal cancer: A systematic review of clinical characteristics.

Journal of Clinical Oncology Wan Ying Tan, Ursula M. A. Medeiros Araujo de Matos, Victoria Forbes Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.122

122 Background: Tumor lysis syndrome (TLS) is an oncologic emergency resulting from the release of potassium, phosphorus, and nucleic acids from tumor cells. While rare in colorectal cancer (CRC), TLS is linked with high mortality, and literature is limited. This study aims to summarize the clinical characteristics of patients with TLS in CRC. Methods: We conducted a systematic review of TLS in CRC through a comprehensive literature search in PubMed and manual searches from January 1st, 1993, up to September 13th, 2024. Keywords included "Tumor Lysis Syndrome," "Colorectal Cancer," and "Colon Cancer." 32 studies were found, identifying 11 spontaneous and 22 therapy-related TLS cases. Quantitative and qualitative data were extracted for descriptive analysis. Results: A total of 33 patients (16 males and 15 females) had a mean age of 56.5 ± 17.8 years at TLS diagnosis. The mean ages for males and females were 58.3 ± 7.1 and 55.8 ± 13.7 years, respectively (p=0.59). The primary histology was adenocarcinoma (92%) followed by neuroendocrine (8%) (data unavailable for 9 patients). Among 15 patients with grading information, Grade 2 tumors were most common (53%), followed by Grade 3 (40%) and Grade 1 (7%). Staging data was available for 32 patients. Most patients had Stage IV disease (94%), with frequent metastases to the liver (93%), lungs (30%), and bones (10%). Hyperuricemia is present in all patients (1 patient without data). Acute kidney injury (AKI) was present in all patients (4 patients without data). Hyperphosphatemia was found in 82% of patients (5 patients without data). Hypocalcemia was noted in 52% (10 patients without data), and hyperkalemia was found in 74% (6 patients without data). Out of the 33 patients, 11 experienced spontaneous TLS (33%) and 22 had therapy-related TLS (67%). Duration of TLS onset following therapy was available for 17 patients, including one outlier at 30 days on Capecitabine. The mean duration for therapy-related TLS, excluding the outlier, was 3.8 ± 2.5 days. Among the 22 patients on therapy, 59% received 5-Fluorouracil (5-FU)-based treatment. 31% of those receiving 5-FU had combination therapy with Bevacizumab. Death occurred in 59% of patients, with data missing for 4 patients. Conclusions: TLS in colorectal cancer (CRC) is associated with a mortality rate of up to 59% and shows no gender preference. Identifying predictive factors is crucial for TLS prophylaxis. Patients with TLS in CRC often present with Stage IV disease, liver metastasis, hyperuricemia, and acute kidney injury (AKI).

Effect of adjuvant radiotherapy after endoscopic resection of early esophagus cancer to prevent new intraluminal mucosal recurrence.

Journal of Clinical Oncology Hirofumi Fukushima, Awatsu Takahito, Shunsuke Adachi et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.381

381 Background: Endoscopic resection (ER) is effective for treating T1a early esophageal squamous cell carcinoma (ESCC). Occasional distant metastasis and recurrence are inevitable invasion in depth of muscularis mucosa(MM). Additional surgical resection is an effective means for cure and prevent recurrence, but it imposes a heavy physical burden. Chemoradiation therapy (CRT) is a comparable alternative to surgery. Not all patients will want those additional treatment. Another problem is the occurrence of new esophagus intraluminal mucosal recurrence. After endoscopic treatment, there is an increased risk of scarring and deformity. But there are few reports of the effectiveness of additional RT in suppressing new lesions. This study was designed to verify the efficacy of not only curability but also suppressive effect the occurrence of new lesions additional treatment of T1a(MM) ESCC. Methods: This study was a retrospective study. We reviewed 71 consecutive patients who underwent ER followed by clinical stage I (T1a: MM) ESCC. We compared patients in the radiotherapy group or non-radiotherapy group after ER. Patients of radiotherapy group received radiation within 3 months after ER. All patients underwent regular follow-up. Recurrence, recurrence-free survival, cancer-specific survival, overall survival, and complications were evaluated. Results: There were 34 cases of radiotherapy group and 37 cases of non-radiotherapy group. 3 patients (8.9 %) in the radiotherapy group experienced intraluminal mucosal recurrence, and 2 patients (6.6 %) experienced local recurrence. On the other hand, in the non-radiotherapy group, 9 patients (24.3 %) experienced intraluminal mucosal recurrence, and 7 patients (18.9 %) experienced local recurrence (intraluminal mucosal recurrence: p&lt; 0.05, local recurrence p=0.14). The recurrent group received chemotherapy. The 3-year cumulative recurrence-free survival was 97 % in the radiotherapy group and 83.7 % in the non-radiotherapy group (p&lt; 0.05). No severe radiation toxicities were recorded. Conclusions: The radiotherapy after ESD reduced the risk of lymph nodes recurrence not only local lymph node recurrence but also new intraluminal mucosal recurrence, and safe and effective therapeutic strategy.

Autophagy-related 7 (ATG7) regulates food intake and liver health during asparaginase exposure

Journal of Biological Chemistry Brian A. Zalma, Maria Ibrahim, Flavio C. Rodriguez-Polanco et al. Feb 01, 2025 DOI: 10.1016/j.jbc.2025.108171

A multimodal deep learning approach for the prognostic stratification of patients with colorectal cancer (CRC).

Journal of Clinical Oncology Nuha Shaker, Noor Shaker, Aatur D. Singhi Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.287

287 Background: Traditional prognostic systems like the AJCC TNM staging for colorectal cancer (CRC) often fall short in predicting long-term patient outcomes. These systems often rely on limited pathologic features, leading to generalized approaches to treatment despite diverse tumor heterogeneity, such as the complex interaction between the tumor-host microenvironment. There is therefore a pressing need for more accurate, scalable tools to enhance decision-making and predict outcomes for patients with CRC. Methods: Tumor sections from 191 CRC patients were comprehensively stained for CD8 to examine CD8-positive tumor-infiltrating lymphocytes (TILs). To account for tumor heterogeneity, multiple areas of the tumor were evaluated to include intertumoral and peritumoral areas. Slides were digitized and quantitatively analyzed using a cloud-based platform (SpatialX Diagnostics, Inc. USA). Additionally, clinicopathologic features including patient demographics, 8th edition AJCC staging, lymphovascular invasion (LVI), perineural invasion (PNI), mismatch repair (MMR) protein status, tumor location, presence/development of distant metastases, and patient follow-up were collected. Merging CD8 AI findings with clinicopathologic features, a complete data set was available for 175 patients. Cases were randomly assigned into 70% training and 30% validation. In the training set, unsupervised artificial intelligence (AI) models integrated clinicopathologic data and CD8-positive TIL counts using vision transformer models. The final model combined spatially resolved pathologic features with clinical variables to statistically predict overall survival (OS) and distant metastasis risk (DMR). Results: In the validation cohort, the model stratified patients into two groups based on a deep learning-derived risk score, with statistically significant differences between low-risk and high-risk groups for OS (p&lt;0.02) and DMR prediction (p&lt;0.0001), For OS prediction, the model selected tumor site, PNI, MMR status, epithelial and stromal CD8-positive TILs, and 5 deep vision features as the top 10 clinically significant features. For DMR prediction, the age, T- and N-stage, PNI, and 6 deep vision-derived features as key predictors. Conclusions: As captured by vision transformers, the distribution and spatial arrangement of CD8-positive TILs are critical factors in patient stratification for OS and DMR. AI-driven models like the one herein offer the potential for more personalized management strategies, advancing CRC management and improving patient outcomes beyond traditional prognostic staging systems and parameters.

Phase 2 trial of defactinib in combination with avutometinib in patients with advanced diffuse-type gastric cancer.

Journal of Clinical Oncology Ryan H. Moy, Lawrence Wen Wu, Hope Cho et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.tps505

TPS505 Background: Diffuse-type gastric cancer (DGC) accounts for approximately one third of gastric cancer diagnoses. DGC is characterized by poor differentiation, discohesive growth, frequent peritoneal spread, chemoresistance, and inferior survival compared to intestinal-type gastric cancer. Moreover, DGC is commonly genomically stable and often lacks clinically actionable targets such as ERBB2 amplification. Alterations enriched in DGC including loss-of-function CDH1 mutations and gain-of-function RHOA mutations can facilitate increased focal adhesion kinase (FAK) signaling that drives tumor proliferation, invasiveness, and metastasis. Recent preclinical studies demonstrated that the FAK inhibitor defactinib can inhibitor DGC growth in vitro and in vivo . FAK inhibitor monotherapy leads to compensatory mitogen-activated protein kinase (MAPK) pathway upregulation, which can be overcome with combined FAK and MEK inhibition. In preclinical DGC xenograft models, defactinib plus the RAF/MEK clamp avutometinib led to deep tumor regressions, suggesting synergistic activity of the combination. The goal of this study is to investigate the efficacy and tolerability of avutometinib plus defactinib in patients with advanced DGC refractory to standard therapy. Methods: This investigator-initiated, multicenter phase 2 trial will enroll 27 patients with metastatic/unresectable gastric or gastroesophageal junction carcinoma classified as diffuse, poorly cohesive, signet ring cell, or mixed type with progression on at least one line of therapy including platinum/fluorouracil chemotherapy. Patients with known pathogenic CDH1 and/or RHOA alterations regardless of histology are also eligible. Patients must have ECOG PS 0/1 and can have either measurable or evaluable non-measurable disease per RECIST 1.1 criteria. Avutometinib is given 3.2 mg orally twice weekly and defactinib is given 200 mg orally twice a day, both for 3 weeks on/1 week off for each 28-day cycle. The primary endpoint is 6-month PFS rate, with secondary endpoints including ORR, OS, DOR, and tolerability. Exploratory studies will interrogate FAK/MAPK pathway activation, ctDNA dynamics, and the impact of the combination of avutometinib/defactinib on the tumor microenvironment from pre- and on-treatment biopsies. The trial was opened for enrollment in August 2024. Clinical trial information: NCT06487221 .

Fruquintinib plus best supportive care for patients with metastatic colorectal cancer: Characterization of patients who had an overall survival of ≥10 months in the FRESCO-2 study.

Journal of Clinical Oncology Stefan Kasper, Andrea Sartore-Bianchi, Violaine Randrian et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.142

142 Background: Fruquintinib (F) is a highly selective, oral tyrosine kinase inhibitor of all 3 vascular endothelial growth factor receptors (VEGFRs -1, -2, -3) that is approved by the US FDA and in the EU, UK, and Japan for previously treated metastatic colorectal cancer (mCRC), regardless of biomarker status. FRESCO-2 (NCT04322539) met its primary endpoint demonstrating significantly improved overall survival (OS) with F + best supportive care (BSC) vs placebo (P) + BSC. This subgroup analysis assessed landmark survival of all FRESCO-2 patients (pts), and baseline (BL) characteristics and safety data of pts treated with F who had OS ≥10 months (mos) compared with the intent-to-treat (ITT) population (pop). Methods: Pts were randomized 2:1 to receive F 5 mg or matching P, by mouth, once daily, 3 weeks on, 1 week off, + BSC. Pts had received prior chemotherapy, anti-VEGF therapy and, if RAS wild type, anti-EGFR therapy; and had prior exposure to trifluridine/tipiracil (TAS-102) and/or regorafenib. The hazard ratio (HR) between the two treatment arms was calculated from a stratified Cox proportional hazard model with treatment group as the only covariate in the model. Results: In the ITT pop, OS was improved with F vs P (HR 0.66); OS rates (95% confidence intervals [CIs]) at 6 and 9 mos were 60.4% (55.9–64.9) vs 41.5% (35.0–48.0) and 41.1% (36.4–45.8) vs 28.2% (22.1–34.3), respectively. Progression-free survival (PFS) rates (95% CIs) at 6 and 9 mos were 23.8% (19.7–28.0) vs 1.1% (0–2.6) and 11.3% (8.1–14.6) vs 0.5% (0–1.6), respectively. Of 461 pts who received F, 113 (24.5%) had OS ≥10 mos (range 10.0–18.9) with a median duration of F treatment of 6.3 mos (range 0.7–19.1). Among pts receiving F, a higher proportion (≥10% difference) of pts with OS ≥10 mos had no liver metastases (mets) and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 at BL compared with the ITT pop (Table). In pts with OS ≥10 mos, 61.9% experienced a grade ≥3 treatment-emergent adverse event compared with 62.7% in the ITT pop. Conclusions: Longer-term OS and PFS rates at 6 and 9 mos were higher with F vs P in the FRESCO-2 ITT pop. The data show a higher proportion of pts with OS ≥10 mos had an absence of liver mets and ECOG PS 0 at BL than the ITT pop. The safety profile of F in pts with OS ≥10 mos was consistent with the ITT pop. Clinical trial information: NCT04322539 . BL characteristics of pts treated with F with OS ≥10 mos vs ITT pop. BL characteristic Pts with OS ≥10 mos (n=113) ITT pop(n=461) ECOG PS (0 / 1), % 54.0 / 46.0 42.5 / 57.5 Median time since 1 st CRC diagnosis, mos 52.0 47.2 Primary tumor location at 1 st diagnosis (colon / rectum / both), % 51.3 / 35.4 / 13.3 60.5 / 31.0 / 8.5 Primary site at 1 st diagnosis (colon left / colon right), % 42.5 / 15.9 41.6 / 21.0 Liver mets, % 58.4 73.5 Median duration of mCRC, mos 42.7 37.9 Prior lines of therapy for mCRC (≤3 / &gt;3), % 26.5 / 73.5 27.1 / 72.9 Prior TAS-102, % 46.9 52.1 Prior regorafenib, % 12.4 8.7

Epidemiological characteristics of gastric and pancreatic cancers in Latin America: GASPAR (LACOG 0222) study.

Journal of Clinical Oncology Renata D'Alpino Peixoto, Victor Hugo Fonseca Jesus, Diogo Bugano Diniz Gomes et al. Feb 01, 2025 DOI: 10.1200/jco.2025.43.4_suppl.369

369 Background: Gastric (GC) and pancreatic cancer (PC) have poor prognosis representing major public health challenges, particularly in Latin America. Real-world data are limited. GASPAR (LACOG 0222) study addresses this gap by creating a multicenter database to analyze epidemiological, clinical, and pathological data, treatments, and outcomes for patients (pts) with GC and PC. Methods: This retrospective and prospective observational cohort study enrolled pts from 7 research sites in 3 LATAM countries with metastatic/locally advanced not amenable to curative intent GC (Cohort A) and PC (Cohort B) diagnosed from January 2019. Data were collected from medical records. ( NCT05924789 ). Results: 201 pts were included: 122 with GC (Cohort A) and 79 with PC (Cohort B). 150 (75%) from Brazil, 29 (14%) from Argentina, and 22 (11%) from Colombia. Median age at diagnosis was 69 years (IQR 57-78), 70 (35%) had history of tobacco use, and 153 (76%) were covered by private healthcare (Table). In Cohort A (GC), HER2 status was assessed in 105 (86%) pts, with 12 (11%) HER2-positive; PD-L1 was tested in 87 (71%): 55 (63%) had ≥1% expression and 28% had ≥10%; all 88 (72%) patients who had MMR tested had MMR proficient. First-line treatment was given to 107 (88%) pts: 78 (73%) chemotherapy (CT) alone (FOLFOX in 43 [40%]; FLOT in 16 [15%]); 23 (21%) CT + immunotherapy; and 7 (7%) CT + anti-HER2. Only 59 (48%) pts received second-line treatment and 31 (25%) third-line. With median follow-up (mFUP) of 29 months (CI95% 18.2-50.4), the median progression-free survival (mPFS) at first-line was 5.6 months (CI95% 4.2-6.3) and the median overall survival (mOS) was 11.2 months (CI95% 9.2-14.1). In Cohort B (PC), 67 (85%) pts received first-line treatment: 41 (61%) FOLFIRINOX and 14 (21%) gemcitabine-nab-paclitaxel. 27 (34%) pts received second-line treatment and 10 (13%) third-line. With mFUP of 21 months (CI95% 15.6-NR), the mPFS at first-line was 5.4 months (CI95%3.9-6.4) and the mOS was 10.2 months (CI95% 8.6-13.1). Conclusions: The GASPAR study provides valuable real-world data on GC and PC in Latin America. Notably, the mPFS in both cohorts was slightly lower than historical controls for first-line treatments, while the mOS was similar, suggesting earlier disease progression despite comparable overall survival. Improved therapeutic strategies and healthcare access are needed to enhance outcomes for these populations. Clinical trial information: NCT05924789 . Clinical characteristics. Characteristic GC (Cohort A)N=122 PC (Cohort B)N=79 Median age (IQR), yr 66 (51–78) 71.0 (61–79) Male – n. (%) 58 (56) 40 (51) Race – n. (%) White 67 (55) 71 (90) American Indian or Alaska Native 15 (12) 6 (8) Black 7 (6) 0 Other 7 (6) 0 Not reported 26 (21) 2 (2) Disease status at study entry Locally advanced disease 4 (3) 14 (18) Metastatic disease 118 (97) 65 (82) ECOG status in first-line advanced disease – n. (%) 0-1 75 (70) 45 (67) ≥ 2 13 (12) 3 (4.5) Not reported 19 (17.8) 19 (28.4)